The duration, nature and recurrence rate of brief depressions

Montgomery, Stuart; Montgomery, D. B.; Baldwin, David S.; Green, Mary

doi:10.1016/0278-5846(90)90043-g

Cited by 32 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with recurrent brief depression experience depressive symptoms only intermittently (only 15-20 % of the duration of follow-up) and therefore cannot fulfil criteria for dysthymia ; similarly only 3 % of patients experience brief hypomanic episodes (Montgomery et al 1990). Suicide attempts appear common, especially in the group with combined depression, although this may result from referral bias.…”

Section: What Are the Features In Clinical Samples ?mentioning

confidence: 99%

Recurrent brief depression – more investigations in clinical samples are now required

Baldwin¹

2003

Psychol. Med.

View full text Add to dashboard Cite

Classifications of depression based on secondary care samples may have little relevance in primary care settings, where many patients do not fulfil criteria for major depression; for example, through having depressive symptoms that are either too mild or too brief. And yet many such patients receive antidepressant treatments (antidepressants and various psychotherapies). At a time when the appropriate recognition and treatment of people with depressive symptoms is the subject of much discussion, and there is concern about the burgeoning number of new psychiatric diagnoses, the burden and hazards of depressive disorders need to be emphasized. The paper by Pezawas et al. (2003) (in this issue) reports the findings of an epidemiological study in adolescents and young adults, and provides a detailed description of the prevalence and features of one such disruptive disorder, namely recurrent brief depression.

show abstract

Section: What Are the Features In Clinical Samples ?mentioning

confidence: 99%

Recurrent brief depression – more investigations in clinical samples are now required

Baldwin¹

2003

Psychol. Med.

View full text Add to dashboard Cite

show abstract

“…The current understanding of RBD is of a disorder characterized by episodes of depression recurring monthly over a year that fulfill the full diagnostic criteria for major depressive episodes except for being shorter than the required 2-week duration (DSM-IV-TR;American Psychiatric Association, 2000). Although the occurrence of episodes can be erratic and highly variable, the literature suggests that the majority of episodes have a duration of 1-4 days with an average interepisode interval of 18 days (range 1-5 weeks) (Angst and Dobler-Mikola, 1985;Montgomery et al, 1990). Despite its brief duration, RBD has significant clinical impact because of the frequency and unpredictability of recurrences, severity and the association with increased risk of suicidal behavior (Montgomery et al, 1983;Angst, 1994).…”

Section: Introductionmentioning

confidence: 98%

Lamotrigine in the treatment of recurrent brief depression

Ravindran

Ravindran²

2007

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Recurrent brief depression is a well-recognized subtype of depressive illness with brief episodes of depression alternating with periods of euthymia. The symptoms are often severe, with frequent association to suicidal ideation. Literature suggests frequent nonresponse to first-line antidepressants. Lamotrigine is an anticonvulsant with antidepressant properties, and reported effectiveness in bipolar depression. We report on two patients with recurrent brief depression, nonresponsive to selective serotonin reuptake inhibitors and venlafaxine, and who responded to therapeutic doses of lamotrigine.

show abstract

“…The findings of epidemiological and clinical studies show that many (∼7%) individuals are affected by short-lived ('brief', lasting less than 2 weeks) but highly recurrent episodes of typically severe and markedly impairing depressive symptoms (Angst and Dobler-Mikola, 1985;Montgomery et al, 1990;Maier et al, 1994;Weiller et al, 1994;Carta et al, 2003;Pezawas et al, 2003). The findings of epidemiological and clinical studies show that many (∼7%) individuals are affected by short-lived ('brief', lasting less than 2 weeks) but highly recurrent episodes of typically severe and markedly impairing depressive symptoms (Angst and Dobler-Mikola, 1985;Montgomery et al, 1990;Maier et al, 1994;Weiller et al, 1994;Carta et al, 2003;Pezawas et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression

Baldwin

Green

Montgomery

2014

International Clinical Psychopharmacology

Self Cite

View full text Add to dashboard Cite

'Recurrent brief depression' (RBD) is a common, distressing and impairing depressive disorder for which there is no current proven pharmacological or psychological treatment. This multicentre, randomized, fixed-dose, parallel-group, placebo-controlled study of the reversible inhibitor of monoamine oxidase moclobemide (450 mg/day) and the tricyclic antidepressant imipramine (150 mg/day) evaluated the potential efficacy of active medication, when compared with placebo, in patients with recurrent brief depression, recruited in the mid-1990s. After a 2-4-week single-blind placebo run-in period, a total of 35 patients were randomized to receive double-blind medication for 4 months, but only 16 completed the active treatment period. An intention-to-treat analysis of the 34 evaluable patients found no evidence for the efficacy of moclobemide or imipramine, when compared with placebo, in significantly reducing the severity, duration or frequency of depressive episodes. A total of 28 patients experienced at least one adverse event, and four patients engaged in nonfatal self-harm. Limitations of the study include the small sample size and the high rate of participant withdrawal. The lack of efficacy of these antidepressant drugs and the previous finding of the lack of efficacy of the selective serotonin reuptake inhibitor fluoxetine together indicate that medications other than antidepressant drugs should be investigated as potential treatments for what remains a common, distressing and potentially hazardous condition.

show abstract

The duration, nature and recurrence rate of brief depressions

Cited by 32 publications

References 4 publications

Recurrent brief depression – more investigations in clinical samples are now required

Recurrent brief depression – more investigations in clinical samples are now required

Lamotrigine in the treatment of recurrent brief depression

Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression

Contact Info

Product

Resources

About